The inflammatory bowel diseases (IBDs), Crohn's disease and ulcerative colitis, present an ever increasing burden to the healthcare systems in the Western world. Scotland in particular has seen a significant increase in both diseases, particularly Crohn's disease. It is thus of paramount importance that secondary care services within Scotland are equipped to cope with this increased demand at a time when the treatment options are broadening, patients expectations are increasing and healthcare budgets face major restriction. This article outlines some aspects of optimal delivery of an IBD service in secondary care.
HendersonPHansenRCameronFL. Rising incidence of pediatric inflammatory bowel disease in Scotland. Inflamm Bowel Dis2012; 18: 999–1005.
2.
Van LimbergenJRussellRKDrummondHE. Definition of phenotypic characteristics of childhood-onset inflammatory bowel disease. Gastroenterology2008; 135: 1114–1122.
3.
SebastianSJenkinsHMcCartneyS. The requirements and barriers to successful transition of adolescents with inflammatory bowel disease: differing perceptions from a survey of adult and paediatric gastroenterologists. J Crohns Colitis2012; 6: 83–844.
4.
JohnsonGJCosnesJMansfieldJC. Review article: smoking cessation as primary therapy to modify the course of Crohn’s disease. Aliment Pharmacol Ther2005; 21: 921–931.
5.
RyanWRLeyCAllanRN. Patients with Crohn’s disease are unaware of the risks that smoking has on their disease. J Gastrointest Surg2003; 7: 706–711.
6.
WrightAJTakeichiCWhitwellSC. The impact of genetic testing for Crohn’s disease, risk magnitude and graphical format on motivation to stop smoking: an experimental analogue study. Clin Genet2008; 73: 306–314.
7.
HilsdenRJHodginsDCzechowskyD. Attitudes toward smoking and smoking behaviors of patients with Crohn’s disease. Am J Gastroenterol2001; 96: 1849–1853.
AveyardP. The place of varenicline in smoking cessation treatment. Thorax2008; 63: 666–668.
10.
SteadLFLancasterT. Group behaviour therapy programmes for smoking cessation. Cochrane Database Syst Rev2005; 2: CD001007–CD001007.
11.
HafeezRGreenhalghRRajanJ. Use of small bowel imaging for the diagnosis and staging of Crohn’s disease – a survey of current UK practice. Br J Radiol2011; 84: 508–517.
12.
LeeSSKimAYYangSK. Crohn disease of the small bowel: comparison of CT enterography, MR enterography, and small-bowel follow-through as diagnostic techniques. Radiology2009; 251: 751–761.
13.
ParienteBCosnesJDaneseS. Development of the Crohn’s disease digestive damage score, the Lémann score. Inflamm Bowel Dis2011; 17: 1415–1422.
14.
RøsethAGAadlandEGrzybK. Normalization of faecal calprotectin: a predictor of mucosal healing in patients with inflammatory bowel disease. Scand J Gastroenterol2004; 39: 1017–1020.
15.
BunnSKBissetWMMainMJ. Fecal calprotectin: validation as a noninvasive measure of bowel inflammation in childhood inflammatory bowel disease. J Pediatr Gastroenterol Nutr2001; 33: 14–22.
16.
GayaDRLyonTDDuncanA. Faecal calprotectin in the assessment of Crohn’s disease activity. QJM2005; 98: 435–441.
17.
LambCAMohiuddinMKGicquelJ. Faecal calprotectin or lactoferrin can identify postoperative recurrence in Crohn’s disease. Br J Surg2009; 96: 663–674.
18.
CostaFMumoloMGBelliniM. Role of faecal calprotectin as non-invasive marker of intestinal inflammation. Dig Liver Dis2003; 35: 642–647.
19.
TibbleJASigthorssonGBridgerS. Surrogate markers of intestinal inflammation are predictive of relapse in patients with inflammatory bowel disease. Gastroenterology2000; 119: 15–22.
20.
CostaFMumoloMGCeccarelliL. Calprotectin is a stronger predictive marker of relapse in ulcerative colitis than in Crohn’s disease. Gut2005; 54: 364–368.
21.
PhanVHvan LangenbergDRGraftonR. Research: a dedicated inflammatory bowel disease service quantitatively and qualitatively improves outcomes in less than 18 months: a prospective cohort study in a large metropolitan centre. Frontline Gastroenterol2012; 3: 137–142.
22.
MawdsleyJEIrvingPMMakinsRJ. Optimizing quality of outpatient care for patients with inflammatory bowel disease: the importance of specialist clinics. Eur J Gastroenterol Hepatol2006; 18: 249–253.
23.
NguyenGCNugentZShawS. Outcomes of patients with Crohn’s disease improved from 1988 to 2008 and were associated with increased specialist care. Gastroenterology2011; 141: 90–97.
24.
SackCPhanVAGraftonR. A chronic care model significantly decreases costs and healthcare utilisation in patients with inflammatory bowel disease. J Crohns Colitis2012; 6: 302–310.
25.
KaplanGGMcCarthyEPAyanianJZ. Impact of hospital volume on postoperative morbidity and mortality following a colectomy for ulcerative colitis. Gastroenterology2008; 134: 680–687.
26.
KennedyEDRothwellDMCohenZ. Increased experience and surgical technique lead to improved outcome after ileal pouch-anal anastomosis: a population-based study. Dis Colon Rectum2006; 49: 958–965.
PrefontaineESutherlandLRMacdonaldJK. Azathioprine or 6-mercaptopurine for maintenance of remission in Crohn’s disease. Cochrane Database Syst Rev2009; 1: CD000067–CD000067.
29.
PrefontaineEMacdonaldJKSutherlandLR. Azathioprine or 6-mercaptopurine for induction of remission in Crohn’s disease. Cochrane Database Syst Rev2010; 6: CD000545–CD000545.
30.
GardinerSJGearryRBBeggEJ. Thiopurine dose in intermediate and normal metabolizers of thiopurine methyltransferase may differ three-fold. Clin Gastroenterol Hepatol2008; 6: 654–660; quiz 604.
31.
AnsariAArenasMGreenfieldSM. Prospective evaluation of the pharmacogenetics of azathioprine in the treatment of inflammatory bowel disease. Aliment Pharmacol Ther2008; 28: 973–983.
32.
DubinskyMCReyesEOfmanJ. A cost-effectiveness analysis of alternative disease management strategies in patients with Crohn’s disease treated with azathioprine or 6-mercaptopurine. Am J Gastroenterol2005; 100: 2239–2247.
33.
WinterJWalkerAShapiroD. Cost-effectiveness of thiopurine methyltransferase genotype screening in patients about to commence azathioprine therapy for treatment of inflammatory bowel disease. Aliment Pharmacol Ther2004; 20: 593–599.
34.
OstermanMTKunduRLichtensteinGR. Association of 6-thioguanine nucleotide levels and inflammatory bowel disease activity: a meta-analysis. Gastroenterology2006; 130: 1047–1053.
35.
CuffariCHuntSBaylessT. Utilisation of erythrocyte 6-thioguanine metabolite levels to optimise azathioprine therapy in patients with inflammatory bowel disease. Gut2001; 48: 642–646.
36.
SparrowMPHandeSAFriedmanS. Allopurinol safely and effectively optimizes tioguanine metabolites in inflammatory bowel disease patients not responding to azathioprine and mercaptopurine. Aliment Pharmacol Ther2005; 22: 441–446.
37.
SparrowMPHandeSAFriedmanS. Effect of allopurinol on clinical outcomes in inflammatory bowel disease nonresponders to azathioprine or 6-mercaptopurine. Clin Gastroenterol Hepatol2007; 5: 209–214.
38.
AlfadhliAAMcDonaldJWFeaganBG. Methotrexate for induction of remission in refractory Crohn’s disease. Cochrane Database Syst Rev2005; 1: CD003459–CD003459.
39.
FeaganBGFedorakRNIrvineEJ. A comparison of methotrexate with placebo for the maintenance of remission in Crohn’s disease. North American Crohn’s Study Group Investigators. N Engl J Med2000; 342: 1627–1632.
40.
ColtartIBlackmoreLCaisleyJ. Parenteral methotrexate for patients with Crohn’s disease: how to develop a high-quality and safe self-administration service. Frontline Gastroenterol2012; 3: 36–38.
41.
National Institute for Health and Clinical Excellence. NICE Technology Appraisal Guidance 187: Infliximab (review) and adalimumab for the treatment of Crohn’s Disease, http://www.nice.org.uk/nicemedia/live/12985/48552/48552.pdf (2010, accessed July 2012).
42.
MowatCColeAWindsorA. IBD Section of the British Society of Gastroenterology. Guidelines for the management of inflammatory bowel disease in adults. Gut2011; 60: 571–607.
43.
BreynaertCFerranteMFidderH. Tolerability of shortened infliximab infusion times in patients with inflammatory bowel diseases: a single-center cohort study. Am J Gastroenterol2011; 106: 778–785.
